Is FOLD Stock Still the Best Pick Among Its Peers?
Here is how Amicus Therapeutics (FOLD) stacks up against its peers in size, valuation, growth and margin.
- FOLD’s operating margin of 8.8% is modest, and higher than most peers – though lower than REGN (27.0%).
- FOLD’s revenue growth of 28.3% in the last 12 months is strong, outpacing VRTX, REGN, ALNY, AMGN but lagging ARGX.
- FOLD’s stock is down 35.4% in last 1 year, and trades at a PE of -77.6; it underperformed VRTX, ARGX, ALNY, AMGN.
As a quick background, Amicus Therapeutics is focused on discovering and delivering precision medicines for rare diseases, including treatments for Fabry and Pompe diseases.
| FOLD | VRTX | ARGX | REGN | ALNY | AMGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.3 | 100.8 | 39.9 | 61.0 | 59.2 | 157.4 |
| Revenue ($ Bil) | 0.5 | 11.4 | 2.6 | 14.2 | 2.3 | 34.9 |
| PE Ratio | -77.6 | 27.7 | 37.5 | 13.7 | -219.7 | 23.8 |
| LTM Revenue Growth | 28.3% | 10.5% | 83.2% | 5.4% | 17.2% | 12.9% |
| LTM Operating Margin | 8.8% | -1.7% | 8.3% | 27.0% | -4.9% | 23.5% |
| LTM FCF Margin | 0.3% | 30.6% | – | 25.0% | -3.2% | 30.4% |
| 12M Market Return | -35.4% | -18.3% | 26.0% | -51.1% | 70.3% | -6.7% |
Why does this matter? FOLD just went up 24.3% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell FOLD Stock to see if Amicus Therapeutics holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through FOLD Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| FOLD | 28.3% | 32.3% | 21.3% | 7.8% |
| VRTX | 10.5% | 11.7% | 10.5% | 17.9% |
| ARGX | 83.2% | 78.6% | 198.6% | -17.4% |
| REGN | 5.4% | 8.3% | 7.8% | -24.3% |
| ALNY | 17.2% | 23.0% | 76.2% | 22.9% |
| AMGN | 12.9% | 18.6% | 7.1% | 1.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| FOLD | 8.8% | 6.4% | -18.4% | -62.1% |
| VRTX | -1.7% | -2.1% | 38.3% | 47.6% |
| ARGX | 8.3% | -0.8% | -34.3% | -176.2% |
| REGN | 27.0% | 28.1% | 30.9% | 38.9% |
| ALNY | -4.9% | -7.9% | -15.4% | -75.7% |
| AMGN | 23.5% | 21.7% | 28.0% | 36.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| FOLD | -60.0 | -51.1 | -27.6 | -14.9 |
| VRTX | 31.4 | -193.9 | 29.0 | 22.3 |
| ARGX | 31.6 | 44.2 | -73.7 | -29.0 |
| REGN | 12.4 | 17.4 | 23.7 | 17.8 |
| ALNY | -156.8 | -108.0 | -54.3 | -25.6 |
| AMGN | 22.7 | 34.2 | 22.9 | 21.6 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.